Value of PTEN and Echocardiography in Predicting the Efficacy of Trimetazidine Combined with Metoprolol in the Treatment of Heart Failure

Figures & data

Table 1 Comparison of Basic Data of Patients with Different Prognosis

	Obvious Improvement (n=34)	General Improvement (n=38)	No Improvement (n=26)	Deterioration (n=2)	F/χ^2	P
Age (year)	62.94±3.56	63.12±3.44	62.87±3.62	63.23±3.84	8.932	0.864
Gender/male [n, %]	25	20	12	1	16.483	0.462
Hypertension[n, %]	23	21	10	1	12.451	0.678
Diabetes[n, %]	23	19	14	2	10.678	0.563

Table 2 Comparison of Curative Effects of Patients with Different Levels of Basic PTEN n/%

PTEN Grouping	n	Obvious Improvement	General Improvement	No Improvement	Deterioration	Total Effectiveness
≤0.34	23	3	12	6	2	15/65.22
0.35~0.53	29	6	13	10	0	19/65.52
0.54~0.64	30	13	8	9	0	21/70.00
≥0.65	18	12	5	1	0	17/94.44
Count	100	34	38	26	2	72/72.00

Figure 1 Expression of PTEN in HF patients. ***P<0.001.

Table 3 Comparison of Basic Echocardiographic Parameters in Patients with Different Prognosis

Groups	n	LVEF/%	SV/mL	E/A	LVFS/%
Obvious improvement	34	45.39±3.87	54.32±2.21	0.48±0.05	28.59±1.24
General improvement	38	44.67±3.68	52.73±4.14	0.41±0.04	27.57±1.18
No improvement	26	40.27±2.56	44.37±3.96	0.26±0.02	24.58±1.14
Deterioration	2	39.41±2.33	42.69±3.78	0.24±0.03	23.96±1.15
F
P

Figure 2 Echocardiographic parameters in HF patients. (A–D) Measurement of LVEF, SV, E/A and LVFS parameters in HF patients under echocardiography. **P<0.01, ***P<0.001.

Figure 3 Correlation between PTEN and echocardiographic parameters. (A) Correlation analysis of serum PTEN relative level and LVEF in HF patients. (B) Correlation analysis of serum PTEN relative level and SV in HF patients. (C) Correlation analysis of serum PTEN relative level and E/A in HF patients. (D) Correlation analysis of serum PTEN relative level and LVES in HF patients.